Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Empowering Community Cancer Care: Promoting Education

October 23rd 2024

In this episode of OncChats: Empowering Community Cancer Care, Dr Woodworth discusses her outreach efforts in the Santa Clarita community, including partnering with organizations like the American Cancer Society, hosting educational panels for women, and providing continuing medical education for local physicians to ensure comprehensive cancer care and awareness.

Empowering Community Cancer Care: Importance of Collaboration

October 23rd 2024

In this episode of OncChats: Empowering Community Cancer Care, experts discuss the significance of community-based cancer care, emphasizing that most cancers are diagnosed locally and highlighting the importance of collaboration between primary care physicians and specialists to provide optimal education and treatment.

Dr Adige on Improving QOL Post–Breast Cancer Treatment

October 21st 2024

Sunil Adige, MD, discusses aspects of post-treatment care that can improve long-term quality of life and reduce the risk of breast cancer recurrence.

Ribociclib Earns Positive CHMP Opinion in HR+/HER2– Early Breast Cancer

October 18th 2024

The CHMP issued a positive opinion recommending the approval of ribociclib plus endocrine therapy in HR+/HER2– early breast cancer at high risk of recurrence.

TROP2 Offers Attractive Therapeutic Target in Breast Cancer and Other Solid Tumors

October 15th 2024

Ian Krop, MD, PhD, and Aditya Bardia, MD, MPH, FASCO, detail how TROP2-directed ADCs have generated excitement in breast cancer and other solid tumors.

Empowering Breast Surgeons: A Call for Collective Action

October 14th 2024

As survival rates continue to rise for patients with breast cancer, innovations are still needed to advance surgical care for these patients.

Assay Predicts Response to Neoadjuvant Atezolizumab Plus Chemotherapy in TNBC

October 13th 2024

The DetermaIO gene expression test was predictive of responses to neoadjuvant atezolizumab plus chemotherapy in early-stage triple-negative breast cancer.

The OncFive: Top Oncology Articles for the Week of 10/6

October 12th 2024

Inavolisib triplet wins FDA approval in PIK3CA+ breast cancer, perioperative pembrolizumab improves EFS in head and neck cancer, and more from OncLive this week.

FDA Approves Single-Dose, Intravenous Paclitaxel Biosimilar for Breast Cancer

October 11th 2024

A single-dose formulation of paclitaxel for injectable suspension has been launched in the United States for metastatic breast cancer.

Dissecting Immunotherapy Options for TNBC

October 11th 2024

Margaret Gatti-Mays MD, MPH, of The James Cancer Hospital at Ohio State University, discusses the available immunotherapy options in triple-negative breast cancer.

FDA Approves Inavolisib Plus Palbociclib/Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, HR+, HER2– Advanced Breast Cancer

October 10th 2024

The FDA approved inavolisib plus palbociclib/fulvestrant for select PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer.

Shining a Light on the Importance of Prevention Strategies During Breast Cancer Awareness Month

October 10th 2024

Sunil Adige, MD, discusses how breast cancer awareness efforts can enable earlier detection, better disease management, and improved patient outcomes.

Dr Adige on the Importance of Breast Cancer Awareness Month

October 10th 2024

Sunil Adige, MD, discusses the importance of recognizing Breast Cancer Awareness Month and highlights key insights into understanding the disease.

Dr Wander on Managing HR+ Advanced Breast Cancer in the Clinic

October 8th 2024

Seth Wander, MD, PhD, discusses how he approaches therapeutic treatment for patients with ER+ advanced breast cancer in the clinic.

ADC and CDK4/6 Inhibitor Decision-Making and Sequencing Questions Abound in Breast Cancer

October 8th 2024

Yuan Yuan, MD, PhD, discusses post-CDK4/6 inhibitor treatment options for HR-positive breast cancer and expansions of the definition of HER2 expression.

Next Generation of CDK Inhibitors Are Breaking Ground in HER2– Breast Cancer

October 7th 2024

Joseph A. Sparano, MD, details the next generation of CDK inhibitors such as BLU-222 targeting CDK2 and PF-07220060 targeting CDK4.

The OncFive: Top Oncology Articles for the Week of 9/29

October 5th 2024

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.

Research Seeks to Establish the Efficacy of Minimally Invasive Breast Cancer Procedures and Tests

October 5th 2024

Yuan Yuan, MD, PhD, discusses the management of node-positive breast cancer and the need for guidance surrounding the use of ctDNA in breast cancer.

OncLive’s September Roundup of Key FDA Approvals in Oncology

October 4th 2024

Here is your snapshot of all treatment options that the FDA approved in September 2024.

Dr McAndrew on a Subgroup Analysis of NATALEE in HR+/HER2– Early Breast Cancer

October 3rd 2024

Nicholas P. McAndrew, MD, MSCE, discusses a subgroup analysis of the NATALEE trial in HR+/HER2– early breast cancer by prior systemic treatment.